Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer

NCT06637215 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2023-11-01
Last updated
2024-11-27

Condition(s) studied

Colorectal CarcinomaDay Surgery

Investigational drug(s) / intervention(s)

laparoscopic colorectal day surgerytraditional laparoscopic colorectal surgery

laparoscopic colorectal day surgery: laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions

traditional laparoscopic colorectal surgery: traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions

Study summary

To investigate the postoperative complication incidence and long-term efficacy between ambulatory surgery for colorectal cancer and traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions。

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients voluntarily joined this study and signed an informed consent form; 2. Age: 18-75 years old; 3. The patient should have a good general condition and no serious internal medicine comorbidities (ASA classification of the American Anesthesiology Association is Grade I\~III); 4. Complete colonoscopy and colonoscopy biopsy, and the pathology is confirmed to be adenocarcinoma/high-level intraepithelial neoplasia; 5. Enhanced CT or MRI examination before surgery, indicating that the tumor diameter is ≤5.0 cm; 6. Preoperative staging: cT1-3NanyM0; 7. Strictly follow the colorectal day surgery plan, and micro-laparoscopic radical colorectal cancer treatment can be adopted; 8. There are no contraindications for abdominal wall nerve block anesthesia or non-opiate analgesic drugs; 9. Does not require conventional anticoagulant therapy or antiplatelet therapy; 10. Relatives or co-residents should be able to provide 24 hours of full escort within at least 72 hours after the operation, the place of residence is not more than a 30-minute drive from the hospital, and they can understand and follow the phased treatment plan of diet, analgesic drugs, etc. after the operation. Exclusion Criteria: 1. Elderly patients with multiple basic diseases; 2. Moderate to severe anemia; 3. Severe hypoproteinemia; 4. Diabetes that is not well controlled; 5. Contraindications to laparoscopic surgery; 6. Cases of emergency surgery due to acute intestinal obstruction, perforation or bleeding; 7. Patients with distant metastases; 8. Patients who are unwilling to sign informed consent or follow-up according to the research plan; 9. People with a history of psychotropic drug abuse and unable to quit or have mental disorders; 10. Patients who live alone or in psychosocial isolation, patients who cannot understand the postoperative nursing process; 11. After the operation, the place of residence is far away from the treated hospital or patients with insufficient medical resources and inconvenient transportation; 12. According to the judgment of the researcher, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the patient\'s research.

Primary outcome measure(s)

  • Recurrence-free survival (DFS) — From enrollment to the end of treatment at 36 months
  • Overall survival (OS) — From enrollment to the end of treatment at 36 months

Trial sites (1)

FacilityCityRegionStatus
First Hospital of China Medical University Shenyang Liaoning Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06637215 on ClinicalTrials.gov ↗ ← All trials in China